Table 1 Patient characteristics
From: Systemic immune-inflammation index in germ-cell tumours
Discovery set | Validation set | |||
|---|---|---|---|---|
N =171 | % | N =181 | % | |
Age (years) | ||||
Median (range) | 30 (17–62) | 30 (16–67) | ||
Histology | ||||
Pure seminoma | 31 | 18 | 33 | 18 |
Non-seminoma or mixed GCT | 127 | 74 | 148 | 82 |
N/A | 13 | 8.0 | ||
Primary tumour | ||||
Gonadal | 143 | 84 | 179 | 99 |
Extragonadal | 28 | 16 | 2 | 1 |
IGCCCG risk group | ||||
Good risk | 90 | 53 | 146 | 81 |
Intermediate risk | 24 | 14 | 19 | 11 |
Poor risk | 57 | 33 | 16 | 8 |
Sites of metastases | ||||
Retroperitoneum | 146 | 85 | 121 | 67 |
Mediastinum | 45 | 26 | 18 | 10 |
Lungs | 84 | 49 | 39 | 22 |
Liver | 62 | 35 | 9 | 5 |
Other | 29 | 17 | 16 | 9 |
Non-pulmonary visceral metastases | 46 | 27 | 8 | 4 |
No. of metastatic sites | ||||
0 | 8 | 5 | 55 | 30 |
1–2 | 103 | 60 | 101 | 57 |
>3 | 60 | 35 | 25 | 13 |
Mean (range) of pretreatment markers | ||||
AFP mIU ml−1 | 4324 (0–164 946) | 998 (0–60 570) | ||
HCG IU ml−1 | 164 474 (0–1 888 840) | 10 633 (0–423 338) | ||
LDH (mkat l−1) | 16 (2–130) | 12 (1.97–81) | ||
